Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Closes
- Sep 25, 2028 (in 698 days)
Similar opportunities open now
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Mar 2027
- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Mar 2027Up to $1.5M
- Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jun 2028
- Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Aug 2027Up to $150K
- Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jul 2029Up to $450K
Classification and identifiers
- Solicitation number
- PAR-27-026
- Assistance listing (CFDA)
- 93.279
Amount
Amount not listed here. Check the official program.
Who can apply
Small businesses, Local government agencies, and Nonprofits can all apply here. Check the eligibility details below to see if your organization fits.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this opportunity
The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.